~~<i id='39B8C028DF'><strike id='39B8C028DF'><tt id='39B8C028DF'><pre id='39B8C028DF'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

author：focus 2025-09-29 20:00:17 - browse：7285

Photo illustration of a single pill on a large white field – opinion coverage from STAT — Adobe

This time last year, members of Congress were working around the clock to draft and pass the Inflation Reduction Act.

One of their goals was to address government spending on health care. But they specifically didn’t want to discourage research into rare disease treatments, so they exempted some of these so-called orphan drugs from the law.

Unfortunately, the exemptions aren’t working as intended. Unless Congress acts, the IRA threatens to unravel one of America’s greatest medical and public policy success stories: the explosion of new treatments for patients living with rare diseases.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Sarepta Duchenne therapy fails to meet primary endpoint in trial

explore

leisure time

focus

explore

Issue1supporterscheerastheywatchelectionresultscomein,Tuesday,Nov.7,inColumbus,Ohio.SueOgrocki/APLas

WSS

Prime Medicine says its gene editing passes test in monkeys

NIH chief: government has fallen behind pharma on clinical trials

White House drug czar issues call for 'recovery

Publishing genetic code of viruses could cause disaster

Medicare must police algorithms in Medicare Advantage, Dems say

Weight loss drugs should be covered by insurers, AMA says

leisure time

leisure time

explore

In Memoriam: Notable people who died in 2023

Ventyx halts psoriasis drug development after lackluster trial results

Novavax promises a turnaround & Lilly roils the obesity market

DeepMind touts AlphaFold's new skills as protein folding AI models face off

23andMe had bad news about my health. I wish a person had delivered it

The health care issue Democrats can’t solve: hospital reform

Tori Bowie and the unacceptable rates of Black maternal death

Medicare’s new pay boost for primary care is angering specialists

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Study suggests Covid rebound is far more common with Paxlovid than without

explore

Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Life sciences investors close nearly $6 billion in new funds

Healthy food access boosts outcomes in two studies

White House drug czar issues call for 'recovery

Inari Medical to buy amputation prevention company LimFlow

leisure time

focus

focus

explore